Estrogen and its role in thyroid cancer

M Derwahl, D Nicula - Endocrine-related cancer, 2014 - erc.bioscientifica.com
Proliferative thyroid diseases are more prevalent in females than in males. Upon the onset of
puberty, the incidence of thyroid cancer increases in females only and declines again after …

Molecular pathways: targeting the cyclin D–CDK4/6 axis for cancer treatment

T VanArsdale, C Boshoff, KT Arndt… - Clinical cancer …, 2015 - aacrjournals.org
Cancer cells bypass normal controls over mitotic cell-cycle progression to achieve a
deregulated state of proliferation. The retinoblastoma tumor suppressor protein (pRb) …

MONARCH 3: abemaciclib as initial therapy for advanced breast cancer

MP Goetz, M Toi, M Campone, J Sohn… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as
monotherapy and in combination with fulvestrant in women with hormone receptor (HR) …

MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy

GW Sledge Jr, M Toi, P Neven, J Sohn… - Journal of clinical …, 2017 - ascopubs.org
Purpose MONARCH 2 (ClinicalTrials. gov identifier: NCT02107703) compared the efficacy
and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus …

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2 Metastatic Breast Cancer

MN Dickler, SM Tolaney, HS Rugo, J Cortés… - Clinical Cancer …, 2017 - aacrjournals.org
Abstract Purpose: The phase II MONARCH 1 study was designed to evaluate the single-
agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 …

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

HS Rugo, P Kabos, JT Beck, G Jerusalem… - NPJ Breast …, 2022 - nature.com
This nonrandomized, open-label, multi-cohort Phase 1b study (NCT02779751) investigated
the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in …

Estrogen signaling multiple pathways to impact gene transcription

M Marino, P Galluzzo, P Ascenzi - Current genomics, 2006 - ingentaconnect.com
Steroid hormones exert profound effects on cell growth, development, differentiation, and
homeostasis. Their effects are mediated through specific intracellular steroid receptors that …

Estrogen receptor pathways to AP-1

PJ Kushner, DA Agard, GL Greene, TS Scanlan… - The Journal of steroid …, 2000 - Elsevier
Estrogen receptor (ER) binds to estrogen response elements in target genes and recruits a
coactivator complex of CBP-pl60 that mediates stimulation of transcription. ER also activates …

Structure–function relationship of estrogen receptor α and β: Impact on human health

P Ascenzi, A Bocedi, M Marino - Molecular aspects of medicine, 2006 - Elsevier
17β-Estradiol (E2) controls many aspects of human physiology, including development,
reproduction and homeostasis, through regulation of the transcriptional activity of its cognate …

Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest

S Paruthiyil, H Parmar, V Kerekatte, GR Cunha… - Cancer …, 2004 - aacrjournals.org
Studies indicate that estrogen receptor (ER) α mediates breast cancer-promoting effects of
estrogens. The role of ERβ in breast cancer is unknown. Elucidating the role of ERβ in the …